John Gerecitano

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

Treatment of Burkitt lymphoma in adults.

Novel small molecules in the treatment of lymphomas.

Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

The future of small molecule inhibitors in lymphoma.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.

Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma.

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.